NOAC Plasma Concentration and Blood Coagulation in Healthy Volunteers

Relationship of edoxaban plasma concentration and blood coagulation in healthy volunteers using standard laboratory tests and viscoelastic analysis

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blood Coagulation Disorder Blood Coagulation Disorders Hematologic Diseases Hemic and Lymphatic Diseases

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Turku University Hospital

Turku, Southwest Finland, 20500, Finland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

healthy

Exclusion criteria

intolerance of the study drug history of bleeding disorder or similar

Treatment and study plan

Edoxaban 60 MG

Drug

Viscoelastic analysis and standard laboratory tests after edoxaban ingestion

Primary outcomes

correlation of edoxaban peak plasma concentrations and viscoelastic analysis

Time frame: 1 day

viscoelastic test values and blood coagulation laboratory parameters

Sponsors and collaborators

Lead sponsor

Turku University Hospital

Other Gov

Collaborators

Helsinki University Central Hospital

Registry information

Official study title

Relationship of Edoxaban Plamsa Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis

Acronym: EdoRot

Important dates

Study start: 2018
Primary completion: 2019
Study completion: 2019
First posted: Sep 12, 2018
Registry last updated: Sep 17, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed